Mintz Levin Represents Cleveland Biolabs, Inc. in $8.4 Million Direct Offering
1/3/2011
New York, NY – Corporate attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Cleveland BioLabs, Inc. (NASDAQ:CBLI), a Buffalo, N.Y- based drug discovery and development company, in the sale of 1,400,000 shares of its common stock, raising gross proceeds of approximately $8.4 million.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.
HFP Capital Markets, LLC and Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq:RODM - News), served as the co-placement agents for the offering.
Mintz Levin corporate members Kenneth Koch and Jeff Schultz led the transaction, assisted by associate Bryan Yoon.
